Filing Details

Accession Number:
0001179110-12-012000
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-30 21:28:05
Reporting Period:
2012-07-26
Filing Date:
2012-07-30
Accepted Time:
2012-07-30 21:28:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
896264 Usana Health Sciences Inc USNA Medicinal Chemicals & Botanical Products (2833) 870500306
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1203346 Doug G Iiekking 3838 West Parkway Blvd
Salt Lake City UT 84120
Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-26 896 $40.59 896 No 4 M Direct
Common Stock Disposition 2012-07-26 896 $43.46 0 No 4 S Direct
Common Stock Acquisiton 2012-07-26 3,939 $26.06 3,939 No 4 M Direct
Common Stock Disposition 2012-07-26 3,939 $43.46 0 No 4 S Direct
Common Stock Acquisiton 2012-07-27 3,175 $28.16 3,175 No 4 M Direct
Common Stock Disposition 2012-07-27 3,175 $43.65 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock-Settled Stock Appreciation Rights Disposition 2012-07-26 16,000 $0.00 16,000 $40.59
Common Stock Stock-Settled Stock Appreciation Rights Disposition 2012-07-26 10,000 $0.00 10,000 $26.06
Common Stock Stock-Settled Stock Appreciation Rights Disposition 2012-07-27 9,200 $0.00 9,200 $28.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2008-04-19 2012-10-19 No 4 M Direct
5,000 2009-07-21 2014-01-21 No 4 M Direct
36,800 2012-07-27 2017-01-27 No 4 M Direct
Footnotes
  1. The shares acquired resulted from the reporting person's settlement of the stock-settled stock appreciation rights desclosed in Table II.